Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | DPP8 | Q6V1X1 | 3/20 | 0.36 |
| ▸ | DPP7 | Q9UHL4 | 3/20 | 0.36 |
| ▸ | DPP4 | P27487 | 2/20 | 0.36 |
| ▸ | DPP9 | Q86TI2 | 2/20 | 0.36 |
| ▸ | ACE | P12821 | 4/20 | 0.34 |
| ▸ | OPRD1 | P41143 | 2/20 | 0.34 |
| ▸ | LMNA | P02545 | 2/20 | 0.34 |
| ▸ | BACE1 | P56817 | 1/20 | 0.34 |
| ▸ | TGM2 | P21980 | 1/20 | 0.33 |
| ▸ | OPRM1 | P35372 | 2/20 | 0.33 |
| ▸ | OPRK1 | P41145 | 1/20 | 0.33 |
| ▸ | POLB | P06746 | 1/20 | 0.33 |
| ▸ | PKM | P14618 | 1/20 | 0.33 |
| ▸ | MAPT | P10636 | 1/20 | 0.33 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.33 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.33 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3369565 | 0.95 | DPP8 (0.38) | DPP8DPP7DPP4DPP9ACE | |
| SCHEMBL6619629 | 0.95 | DPP8 (0.38) | DPP8DPP7DPP4DPP9ACE | |
| SCHEMBL3370863 | 0.85 | DPP8 (0.37) | DPP8DPP7DPP4DPP9ACE | |
| SCHEMBL7275536 | 0.84 | DPP8 (0.36) | DPP8DPP7DPP4DPP9OPRD1 | |
| SCHEMBL3373796 | 0.83 | KMT2A (0.35) | DPP8DPP7DPP4DPP9POLB | |
| SCHEMBL10882100 | 0.80 | DPP8 (0.40) | DPP8DPP7DPP4DPP9ACE | |
| SCHEMBL10885324 | 0.79 | HPGD (0.36) | DPP8DPP7DPP4DPP9ACE | |
| SCHEMBL3372065 | 0.79 | METAP2 (0.37) | DPP8DPP7DPP4DPP9 | |
| SCHEMBL7266833 | 0.78 | DPP8 (0.41) | DPP8DPP7DPP4DPP9OPRD1 | |
| SCHEMBL10825128 | 0.77 | ACE (0.39) | ACELMNAPOLBPKMMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ECZACIBASI-ZENTIVA KIMYASAL URUNLER SANAYI VE TICARET A.S. (TR) | 2007-04-26 | — | — | US | disclosed |
| EP-1513868-B1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL (TR) | 2006-08-09 | — | — | EP | disclosed |
| EP-1513868-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS Eczacibasi Ozgun Kimyasal Urunler Sanayi Ve Ti Caret A.S. (TR) | 2005-03-16 | — | — | EP | disclosed |
| WO-2004000874-A1 | PROCESS FOR THE PRODUCTION OF LISINOPRIL | EOS ECZACIBASI OZGUN KIMYASAL URUNLER SANYI VE TI CARET A.S. (TR) | 2003-12-31 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20070093664-A1 | Process for the production of lisinopril | ACE, LOX, AGT | DPP8 356/4885DPP7 312/4885DPP4 78/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.